UDIARK-125 SYP — Targeted UDCA Oral Suspension 125mg/5ml
A Practical Liquid Form of Ursodeoxycholic Acid
When a patient is prescribed Ursodeoxycholic Acid in liquid form, the formulation and strength matter. UDIARK-125 SYP contains Ursodeoxycholic Acid 125mg/5ml as an oral suspension, supplied in a convenient 100ml PET bottle.
The formulation provides a measured liquid dosage form for use under professional medical guidance in appropriate hepatobiliary conditions. Its use, dose, and treatment duration should always be determined according to the patient's clinical requirement.
💡 Did You Know?
UDCA is the commonly used abbreviation for Ursodeoxycholic Acid, a bile acid used in selected liver and biliary conditions.
UDIARK-125 SYP | INFORMATION
|
Product Attribute |
Details |
|---|---|
|
Brand |
UDIARK-125 SYP |
|
Composition |
Ursodeoxycholic Acid Oral Suspension 125mg/5ml |
|
Strength |
125mg/5ml |
|
Dosage Form |
Oral Suspension |
|
Pack |
100ml PET Bottle |
|
Packaging |
Monocarton |
|
MRP |
₹360.00 |
When Is Ursodeoxycholic Acid Used?
The therapeutic use of Ursodeoxycholic Acid depends on the patient's diagnosis. It is used in specific hepatobiliary conditions rather than as a routine nutritional supplement.
Key Uses at a Glance
1. Primary Biliary Cholangitis
UDCA is an established treatment for primary biliary cholangitis (PBC), a chronic disease affecting the small bile ducts in the liver.
2. Selected Cholesterol Gallstones
In appropriately selected patients, UDCA can be used to help dissolve certain non-calcified cholesterol gallstones.
3. Cholestatic Liver Conditions
UDCA may be prescribed for selected disorders involving cholestasis and bile-flow abnormalities, depending on specialist assessment.
4. Certain Pediatric Hepatobiliary Conditions
Liquid UDCA preparations may be prescribed in selected pediatric situations, with dosing carefully calculated according to body weight.
Remember: The suitability of UDCA depends on the specific disease, gallstone characteristics and overall clinical condition.
What Makes UDCA Clinically Useful?
After administration, Ursodeoxycholic Acid becomes part of the bile-acid pool and influences the composition and properties of bile. It can reduce cholesterol saturation in bile, which is relevant to the gradual dissolution of suitable cholesterol gallstones.
UDCA also has important effects in cholestatic liver disease and is used as an established therapy for PBC.
The Science in Simple Terms
|
UDCA Action |
What It Means |
|---|---|
|
Changes bile composition |
Helps alter the bile-acid environment. |
|
Lowers cholesterol saturation |
Supports dissolution of suitable cholesterol stones. |
|
Influences bile flow |
Supports bile-flow-related processes. |
|
Supports hepatobiliary therapy |
Has an established role in selected cholestatic diseases. |
In short: UDIARK-125 SYP delivers UDCA through a convenient oral suspension, while the therapeutic effect depends on the diagnosed condition and prescribed regimen.
How Should UDIARK-125 SYP Be Taken?
There is no single standard dose for every patient. Ursodeoxycholic Acid dosing varies according to the indication, body weight, clinical response, and prescribing instructions.
Different medical conditions can require different weight-based regimens. Therefore, patients should never calculate their own dose simply from the 125mg/5ml concentration.
Administration Checklist
-
Use the prescribed quantity according to your doctor's instructions.
-
Measure the liquid accurately using a suitable measuring device.
-
Shake the suspension properly before administration.
-
Take it according to the prescribed schedule for consistent treatment.
-
Continue recommended monitoring when long-term treatment is required.
Dosage caution: Never self-adjust, double or discontinue the dose without consulting your healthcare professional.
The right formulation works best when paired with the right prescription and responsible administration.
What Should You Know About Possible Side Effects?
Most patients can tolerate Ursodeoxycholic Acid, although adverse reactions may occur. Diarrhoea and changes in stool consistency are recognized gastrointestinal effects, while some less common or rare reactions require medical attention.
Common Effects
|
Possible Effect |
Quick Explanation |
|---|---|
|
Diarrhoea |
Loose or frequent stools may occur. |
|
Soft Stools |
Temporary changes in stool consistency may be noticed. |
|
Nausea |
Some patients may experience a feeling of sickness. |
|
Vomiting |
Vomiting can occur in some individuals. |
Serious or Rare Effects
|
Possible Effect |
Quick Explanation |
|---|---|
|
Severe Abdominal Pain |
Persistent or severe pain should be medically assessed. |
|
Gallstone Calcification |
Rarely, gallstones may become calcified during treatment. |
|
Liver Function Deterioration |
Rare complications may occur in patients with advanced liver disease. |
|
Urticaria |
Hives or an allergic skin reaction may occur rarely. |
Persistent, severe, or unexpected symptoms should be reported to the treating healthcare professional.
Before Using UDIARK-125 SYP, Check These Points
✔ Confirm the Diagnosis
UDIARK-125 SYP should be used for an appropriate medical indication.
✔ Know the Gallstone Type
UDCA is not appropriate for every gallstone. Stone characteristics and gallbladder function are important.
✔ Follow Liver Monitoring Advice
Patients receiving UDCA for liver-related conditions may require regular clinical or laboratory monitoring.
✔ Don't Ignore Persistent Diarrhoea
Persistent diarrhoea should be reported because treatment may need medical reassessment.
✔ Tell Your Doctor About Other Medicines
Discuss your current medicines, pregnancy, breastfeeding, or other relevant circumstances before starting treatment.
Safe treatment starts with professional evaluation, not self-medication.
Ready to Grow? Partner With Monark Biocare for UDIARK-125 SYP
UDIARK-125 SYP can add a specialized Ursodeoxycholic Acid oral suspension formulation to an appropriate prescription-focused pharma portfolio. Its 125mg/5ml liquid presentation provides a differentiated product option for suitable markets.
Monark Biocare offers pharma business opportunities including PCD Pharma Franchise, Third Party Manufacturing, Ethical Promotion, Contract Manufacturing, Private Label Manufacturing, Institutional Supply and Pan-India Distribution Support.
Looking for the next opportunity to expand your pharmaceutical portfolio? Partner with Monark Biocare and explore a business model aligned with your market.
Disclaimer
The information provided is for general educational and product-information purposes only. UDIARK-125 SYP should be used only under qualified medical supervision. Dosage, indication, duration, and suitability should be determined by the treating healthcare professional.
Frequently Asked Questions
01. What is the composition of UDIARK-125 SYP?
UDIARK-125 SYP contains Ursodeoxycholic Acid 125mg/5ml in an oral suspension formulation.
02. What is the main use of Ursodeoxycholic Acid?
Ursodeoxycholic Acid is used for selected hepatobiliary conditions, including primary biliary cholangitis and certain suitable cholesterol gallstones.
03. Is UDIARK-125 SYP suitable for every type of gallstone?
No. UDCA is appropriate only for selected gallstones after evaluation by a healthcare professional.
04. What is the most commonly reported side effect?
Diarrhoea or loose stools are among the recognized adverse effects associated with Ursodeoxycholic Acid.
05. Can I decide my own UDIARK-125 SYP dosage?
No. The appropriate dose depends on the medical indication, body weight, and individual treatment requirements. Follow the prescribed regimen.
